• Allan, J.M., Smith, A.G., Wheatley, K., Hills, R.K., Travis, L.B., Hill, D.A., Swirsky, D.M., Morgan, G.J. & Wild, C.P. (2004) Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood, 104, 38723877.
  • Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 28952901.
  • Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., Longo, G., Ammatuna, E., Liso, V., Bosi, A., Barbui, T. & Vannucchi, A.M. (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 114, 14771483.
  • Hernández-Boluda, J.-C., Pereira, A., Cervantes, F., Alvarez-Larrán, A., Collado, M., Such, E., Arilla, M.J., Boqué, C., Xicoy, B., Maffioli, M., Bellosillo, B., Marugán, I., Amat, P., Besses, C. & Guillem, V. (2012) A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood, 119, 52215228.
  • Jones, A.V., Chase, A., Silver, R.T., Oscier, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., Grand, F. & Cross, N.C. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 41, 446449.
  • Pancrazzi, A., Guglielmelli, P., Ponziani, V., Bergamaschi, G., Bosi, A., Barosi, G. & Vannucchi, A.M. (2008) A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. The Journal of molecular diagnostics, 10, 435441.
  • Poletto, V., Rosti, V., Villani, L., Catarsi, P., Carolei, A., Campanelli, R., Massa, M., Martinetti, M., Viarengo, G., Malovini, A., Migliaccio, A.R. & Barosi, G. (2012) A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood, 120, 31123117.
  • Tefferi, A., Pardanani, A., Gangat, N., Begna, K.H., Hanson, C.A., Van Dyke, D.L., Caramazza, D., Vannucchi, A.M., Morra, E., Cazzola, M., Pereira, A., Cervantes, F. & Passamonti, F. (2012) Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia, 26, 14391441.
  • Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 17231735.
  • Varricchio, L., Masselli, E., Alfani, E., Battistini, A., Migliaccio, G., Vannucchi, A.M., Zhang, W., Rondelli, D., Godbold, J., Ghinassi, B., Whitsett, C., Hoffman, R. & Migliaccio, A.R. (2011) The dominant negative beta isoform of the gluco-corticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood, 118, 425436.